Dexcom (DXCM) 8-K Current Report: March 2, 2026
Filed: March 2, 2026
Health Care
Surgical & Medical Instruments & ApparatusDexcom (DXCM) 8-K current report filed with SEC EDGAR on March 2, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 5.02: Departure/Election of Directors or Officers
Dexcom 8-K Mar 2, 2026 Event Analysis
Item 5.02 · Departure/Election of Directors or Officers
- • Sayer returns from leave March 2, 2026, resuming Executive Chairman role; Mark Foletta steps back from interim Lead Independent Director duties
- • New comp package: $610,000 annual base salary as Executive Chairman
- • RSU grant of $2,350,000 fair value, cliff-vesting March 8, 2027, contingent on continued service
- • Prior equity awards continue vesting on original schedules — no accelerated vesting or clawback triggered by leave
- • Sayer excluded from Severance & Change in Control Plan, reducing company's financial exposure if he departs
Other Dexcom 8-K Filings
Get deeper insights on Dexcom
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.